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Background: There is a lack of evidence for the association between intensive statin therapy and
outcomes following vascular surgery. The aim of this study was to evaluate the association between
perioperative statin intensity and in-hospital mortality following open abdominal aortic aneurysm (AAA)
repair.
Methods: Patients undergoing open AAA repair between 2009 and 2015 were identified from the
Premier Healthcare Database. Statin use was classified into low, moderate and high intensity, based on
American College of Cardiology/American Heart Association guidelines. Supratherapeutic intensity was
defined as doses higher than the recommended guidelines.Multivariable logistic regression analyses were
undertaken to assess the association between statin intensity and postoperative major adverse events and
in-hospital mortality.
Results: Of 6497 patients undergoing open AAA repair, 3217 (49⋅5 per cent) received perioperative
statin. Statin users were more likely to present with three or more co-morbidities than non-users (26⋅5
versus 21⋅8 per cent; P< 0⋅001). Unadjusted postoperative mortality was significantly lower in statin users
(2⋅6 versus 6⋅3 per cent; P<0⋅001); however, there was no difference in the risk of developing major
adverse events. Multivariable analysis showed that statin use was associated with lower odds of death
(odds ratio 0⋅41, 95 per cent c.i. 0⋅31 to 0⋅54). Moderate, high and supratherapeutic statin intensities
were not associated with lower odds of death or major adverse events compared with low-intensity statin
therapy.
Conclusion: Statin use is associated with lower odds of death in hospital following open AAA repair.
High-intensity statins were not associated with lower morbidity or mortality.
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Introduction
Morbidity and mortality rates following open repair of
abdominal aortic aneurysm (AAA) remain high. Approxi-
mately 4 per cent of patients undergoing open AAA repair
are not expected to survive the hospital stay1,2, with 27–49
per cent developing postoperative complications3. Sev-
eral pharmacological agents, including aspirin, anticoagu-
lants, beta-blockers and lipid-lowering agents, have been
suggested to reduce adverse events following open AAA
repair4. Recently, statins have been shown to improve
long-term survival after AAA repair. In a meta-analysis5 of
patients who underwent either open or endovascular AAA
repair, lipid-modifying therapies were associated with a 39
per cent reduction in long-term mortality. Among eight
studies included in this meta-analysis, five involved patients
who underwent open AAA repair. However, two6,7 of these
were undertaken by a group of researchers who previously
published multiple clinical trials of questionable scien-
tific validity (an investigation by Erasmus University con-
cluded that these trials were unreliable and contained ficti-
tious data, and so the lead investigator was dismissed from
the university)6–8. The other three retrospective studies
had poor definitions of statin use9,10 and/or did not per-
form analyses specific to patients undergoing open AAA
repair9–11. In a more recent study of patients undergoing
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AAA repair12, the crude risk of in-hospital, 30-day, 90-day
and 1-year postoperative death was similar in statin users
and non-users. This study also did not include an adjusted
analysis for patients who underwent open repair.
Currently, the European Society of Cardiology and the
European Society of Anaesthesiology (ESC/ESA)13 and
American College of Cardiology/American Heart Associ-
ation (ACC/AHA)14 guidelines recommend the initiation
or continuation of statin therapy before non-cardiac oper-
ations. However, evidence demonstrating the effect of
perioperative statin therapy on outcomes following vascu-
lar surgery is currently lacking15. Neither the ESC/ESA
nor the ACC/AHA guidelines provide specific recom-
mendations on the optimum dose or type of statin to be
used. In addition, the effect of statin intensity on outcomes
following vascular surgery is unknown. The aim of the
present study was to examine the association between
statin intensity and in-hospital morbidity and mortality
following open AAA repair.
Methods
The institutional review board at the Johns Hopkins
School of Medicine approved the present study under
exempt status. The Premier Healthcare Database (PHD)
(Premier, Charlotte, North Carolina, USA) was used
to identify the study cohort. The PHD is an all-payer
database that represents about 20 per cent of all annual
inpatient discharges in the USA. It cumulatively maintains
administrative, healthcare utilization and financial data
frommore than 700 hospitals. Hospital participation in this
database is voluntary. At participating hospitals, a full data
abstraction is performed for the included year. Premier
acquires patient data from the health information man-
agement departments at participating hospitals through
its Quality Advisor interface tool. To ensure accuracy of
the data, Premier undertakes data validation at first data
collection and at each subsequent monthly data submis-
sion. Furthermore, it reconciles the submitted data with
the hospital financial statement and thresholds on cases,
charges and cost before publishing these data in the PHD.
When data errors are detected during this phase, Premier
notifies the hospital and makes sure the data are correct
in the source system. The corrected data are resubmitted
to Premier, where the same data processing and validation
guidelines are followed as in the original submission. A
detailed description of the PHD is available elsewhere16.
Setting and patient selection
Included patients were those who underwent open repair
of intact (non-ruptured) AAA between June 2009 and
March 2015 in US hospitals affiliated with Premier. The
ICD-9-CM diagnosis code 441⋅4 was used to identify
admissions primarily for intact AAA, whereas ICD-9-CM
procedure codes 38⋅34, 38⋅36, 38⋅44, 38⋅64, 39⋅25 and
39⋅52 were used to identify open AAA repairs. Exclusion
criteria were: age less than 45 years, admission owing to
trauma and multiple operations for AAA (defined as con-
current open and endovascular AAA repair during the same
hospital admission). In addition, patients receiving a mean
daily dose of statin larger than the 99th percentile were
excluded from the final analysis.
Study co-variables
Data collected included: patient characteristics (age, sex,
race, insurance status, admission type, co-morbidities,
complications and discharge status) and hospital character-
istics (census region, and urban/rural and teaching status).
Patient co-morbidity was classified using the Charl-
son Co-morbidity Index (CCI), with patients grouped
into three co-morbidity levels (CCI score 0–1, 2 and
at least 3)17. The PHD differentiates ICD-9-CM diagno-
sis codes based on whether the patient was admitted with
the code (a co-morbidity), or acquired this code during
admission (a complication). Major adverse events (MAE)
were defined as the presence of any respiratory, cardiac,
gastrointestinal, haemorrhagic, infectious, renal or neuro-
logical complications as defined by Shaw and colleagues18
(Table S1, supporting information). The ICD-9-CM diag-
nosis codes used to capture patient co-morbidities are
listed in Table S2 (supporting information).
To capture in-hospital use of beta-blockers and statins,
the PHD charge description master (CDM) file was
queried. The CDM file contains a list of all bills incurred
by a patient each day. These bills contain information on
drugs, devices and supplies, medical procedures, diagnos-
tic evaluations and other hospital services. Data on drugs
include generic name, amount, unit, route of administra-
tion and number of times administered per day. Patients
were classified as beta-blocker or statin users if they
received any dose of beta-blocker or statin at any time
during their hospital stay (perioperative). The in-hospital
mean daily dose of statin was calculated by dividing the
total amount of statin received during the entire hospital
stay by the total number of days it was administered.
Statin use was further classified based on the ACC/AHA
guideline19, which takes into account the type and daily
dose of statin, into groups receiving low-, moderate- and
high-intensity statins. Patients who received statin doses
higher than the recommended guidelines were classified
as having a supratherapeutic intensity of statin.
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 411–418
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
Statin intensity and mortality after open abdominal aortic aneurysm repair 413
Table 1 Baseline characteristics by statin use and statin intensity
Whole cohort Statin users
No statin Statin Low Moderate High Supratherapeutic
(n=3280) (n=3217) P† (n=277) (n=1987) (n=586) (n=367) P†
Age (years)* 71 (65–77) 70 (65–76) 0⋅043‡ 72 (65–78) 70 (65–76) 69 (63–75) 70 (65–75) 0⋅001‡
Women 935 (28⋅5) 861 (26⋅8) 0⋅116 82 (29⋅6) 524 (26⋅4) 168 (28⋅7) 87 (23⋅7) 0⋅248
Non-white 661 (20⋅2) 673 (20⋅9) 0⋅444 56 (20⋅2) 407 (20⋅5) 110 (18⋅8) 100 (27⋅2) 0⋅013
Insurance 0⋅887 0⋅223
Medicare 2365 (72⋅1) 2342 (72⋅8) 211 (76⋅2) 1445 (72⋅7) 421 (71⋅8) 265 (72⋅2)
Medicaid 97 (3⋅0) 87 (2⋅7) 10 (3⋅6) 58 (2⋅9) 14 (2⋅4) 5 (1⋅4)
Private 675 (20⋅6) 653 (20⋅3) 42 (15⋅2) 407 (20⋅5) 128 (21⋅8) 76 (20⋅7)
Other 143 (4⋅4) 135 (4⋅2) 14 (5⋅1) 77 (3⋅9) 23 (3⋅9) 21 (5⋅7)
CCI score <0⋅001 0⋅453
0–1 1582 (48⋅2) 1381 (42⋅9) 132 (47⋅7) 835 (42⋅0) 251 (42⋅8) 163 (44⋅4)
2 984 (30⋅0) 983 (30⋅6) 77 (27⋅8) 631 (31⋅8) 173 (29⋅5) 102 (27⋅8)
≥3 714 (21⋅8) 853 (26⋅5) 68 (24⋅5) 521 (26⋅2) 162 (27⋅6) 102 (27⋅8)
Admission status 0⋅087 0⋅054
Elective 2620 (79⋅9) 2530 (78⋅6) 203 (73⋅3) 1561 (78⋅6) 480 (81⋅9) 286 (77⋅9)
Urgent 266 (8⋅1) 311 (9⋅7) 38 (13⋅7) 196 (9⋅9) 47 (8⋅0) 30 (8⋅2)
Emergency 394 (12⋅0) 376 (11⋅7) 36 (13⋅0) 230 (11⋅6) 59 (10⋅1) 51 (13⋅9)
Beta-blocker use 2534 (77⋅3) 2874 (89⋅3) <0⋅001 235 (84⋅8) 1779 (89⋅5) 527 (89⋅9) 333 (90⋅7) 0⋅074
Smoking 0⋅135 0⋅227
Never 1126 (34⋅3) 1115 (34⋅7) 94 (33⋅9) 693 (34⋅9) 198 (33⋅8) 130 (35⋅4)
Ever 930 (28⋅4) 971 (30⋅2) 102 (36⋅8) 580 (29⋅2) 179 (30⋅5) 110 (30⋅0)
Current 1224 (37⋅3) 1131 (35⋅2) 81 (29⋅2) 714 (35⋅9) 209 (35⋅7) 127 (34⋅6)
History of MI 366 (11⋅2) 520 (16⋅2) <0⋅001 31 (11⋅2) 289 (14⋅5) 132 (22⋅5) 68 (18⋅5) < 0⋅001
Coronary artery disease 1182 (36⋅0) 1677 (51⋅8) <0⋅001 120 (43⋅3) 985 (49⋅6) 366 (62⋅5) 206 (56⋅1) <0⋅001
Congestive heart failure 205 (6⋅3) 295 (9⋅2) <0⋅001 20 (7⋅2) 179 (9⋅0) 65 (11⋅1) 31 (8⋅4) 0⋅245
Hypertension 2470 (75⋅3) 2680 (83⋅3) <0⋅001 239 (86⋅3) 1636 (82⋅3) 491 (83⋅8) 314 (85⋅6) 0⋅208
Chronic kidney disease 472 (14⋅4) 585 (18⋅2) <0⋅001 51 (18⋅4) 358 (18⋅0) 103 (17⋅6) 73 (19⋅9) 0⋅823
End-stage renal disease 24 (0⋅7) 28 (0⋅9) 0⋅531 2 (0⋅7) 20 (1⋅0) 5 (0⋅9) 1 (0⋅3) 0⋅568
COPD 1158 (35⋅3) 1176 (36⋅6) 0⋅293 106 (38⋅3) 707 (35⋅6) 226 (38⋅6) 137 (37⋅3) 0⋅516
Arrhythmia 422 (12⋅9) 438 (13⋅6) 0⋅373 34 (12⋅3) 266 (13⋅4) 91 (15⋅5) 47 (12⋅8) 0⋅468
Hospital type
Urban 2963 (90⋅3) 2957 (91⋅9) 0⋅025 252 (91⋅0) 1831 (92⋅1) 542 (92⋅5) 332 (90⋅5) 0⋅619
Teaching 1654 (50⋅4) 1706 (53⋅0) 0⋅036 134 (48⋅4) 1044 (52⋅5) 316 (53⋅9) 212 (57⋅8) 0⋅107
Location 0⋅054 0⋅065
Midwest 611 (18⋅6) 627 (19⋅5) 56 (20⋅2) 399 (20⋅1) 100 (17⋅1) 72 (19⋅6)
Northeast 407 (12⋅4) 453 (14⋅1) 33 (11⋅9) 279 (14⋅0) 81 (13⋅8) 60 (16⋅3)
South 1789 (54⋅5) 1652 (51⋅4) 143 (51⋅6) 1006 (50⋅6) 334 (57⋅0) 169 (46⋅0)
West 473 (14⋅4) 485 (15⋅1) 45 (16⋅2) 303 (15⋅2) 71 (12⋅1) 66 (18⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). CCI, Charlson Co-morbidity Index; MI, myocardial
infarction; COPD, chronic obstructive pulmonary disease. †Pearson’s χ2 test, except ‡Mann–Whitney U test.
Statistical analysis
The primary study outcome was in-hospital postoperative
mortality, and the main comparison was statin users versus
non-users. Secondary outcomes included all complications
listed above and the composite MAE. Categorical vari-
ables were compared between study groups using Pearson’s
χ2 test or Fisher’s exact test, as appropriate; continuous
variables, presented as median (i.q.r.), were analysed using
the Mann–Whitney U test. Multivariable logistic regres-
sion analyses were undertaken to assess the association
between statin intensity and postoperative mortality and
MAE. Variables known to have an effect on outcomes and
those with P< 0⋅200 in univariable analysis were selected
for inclusion in the multivariable analysis. Variables were
further selected to achieve a parsimonious model based on
the lowest Akaike information criterion values. P< 0⋅050
was considered statistically significant. Stata® MP version
14⋅1 (StataCorp, College Station, Texas, USA) was used for
statistical analysis.
Results
The range of statin dose by statin type and intensity is
shown in Table S3 (supporting information).
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 411–418
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Table 2 Crude postoperative outcomes by statin use and statin intensity
Whole cohort Statin users
No statin Statin Low Moderate High Supratherapeutic
(n=3280) (n=3217) P* (n=277) (n=1987) (n=586) (n=367) P*
Myocardial infarction 57 (1⋅7) 102 (3⋅2) <0⋅001 7 (2⋅5) 54 (2⋅7) 27 (4⋅6) 14 (3⋅8) 0⋅105†
Major adverse events 1429 (43⋅6) 1418 (44⋅1) 0⋅678 120 (43⋅3) 849 (42⋅7) 263 (44⋅9) 186 (50⋅7) 0⋅042
Respiratory failure 724 (22⋅1) 674 (21⋅0) 0⋅271 55 (19⋅9) 398 (20⋅0) 126 (21⋅5) 95 (25⋅9) 0⋅081
Cardiac 411 (12⋅5) 521 (16⋅2) <0⋅001 51 (18⋅4) 311 (15⋅7) 97 (16⋅6) 62 (16⋅9) 0⋅654
Gastrointestinal 140 (4⋅3) 73 (2⋅3) <0⋅001 6 (2⋅2) 43 (2⋅2) 14 (2⋅4) 10 (2⋅7) 0⋅888†
Haemorrhage 153 (4⋅7) 122 (3⋅8) 0⋅081 7 (2⋅5) 67 (3⋅4) 30 (5⋅1) 18 (4⋅9) 0⋅102†
Infectious 433 (13⋅2) 377 (11⋅7) 0⋅071 30 (10⋅8) 218 (11⋅0) 72 (12⋅3) 57 (15⋅5) 0⋅085
Neurological 18 (0⋅5) 28 (0⋅9) 0⋅122 2 (0⋅7) 17 (0⋅9) 6 (1⋅0) 3 (0⋅8) 0⋅123†
Renal failure 643 (19⋅6) 660 (20⋅5) 0⋅358 56 (20⋅2) 394 (19⋅8) 117 (20⋅0) 93 (25⋅3) 0⋅115
Death from any cause 206 (6⋅3) 83 (2⋅6) <0⋅001 9 (3⋅2) 42 (2⋅1) 20 (3⋅4) 12 (3⋅3) 0⋅168
Death following myocardial infarction 20 (35) 11 (10⋅8) <0⋅001 1 (14) 6 (11) 3 (11) 1 (7) 1⋅000†
Death following major adverse event 182 (12⋅7) 79 (5⋅6) <0⋅001 8 (6⋅7) 40 (4⋅7) 19 (7⋅2) 12 (6⋅5) 0⋅318
Values in parentheses are percentages. *Pearson’s χ2 test, except †Fisher’s exact test.
Table 3 Results of unadjusted and adjusted logistic regression analyses of mortality and major adverse events, by statin use and statin
intensity
Unadjusted Adjusted*
Odds ratio P Odds ratio P
Mortality*
No statin 1⋅00 (reference) 1⋅00 (reference)
Statin use 0⋅40 (0⋅30, 0⋅51) <0⋅001 0⋅41 (0⋅31, 0⋅54) < 0⋅001
Statin intensity
Low 0⋅50 (0⋅25, 0⋅99) 0⋅046 0⋅49 (0⋅24, 0⋅97) 0⋅041
Moderate 0⋅32 (0⋅23, 0⋅45) <0⋅001 0⋅34 (0⋅24, 0⋅47) < 0⋅001
High 0⋅53 (0⋅33, 0⋅84) 0⋅007 0⋅56 (0⋅34, 0⋅90) 0⋅017
Supratherapeutic 0⋅50 (0⋅28, 0⋅91) 0⋅024 0⋅52 (0⋅28, 0⋅95) 0⋅035
Major adverse event†
No statin 1⋅00 (reference) 1⋅00 (reference)
Statin use 1⋅02 (0⋅93, 1⋅13) 0⋅678 0⋅90 (0⋅81, 1⋅00) 0⋅058
Statin intensity
Low 0⋅99 (0⋅77, 1⋅27) 0⋅937 0⋅85 (0⋅66, 1⋅11) 0⋅232
Moderate 0⋅97 (0⋅86, 1⋅08) 0⋅551 0⋅86 (0⋅76, 0⋅96) 0⋅011
High 1⋅05 (0⋅88, 1⋅26) 0⋅555 0⋅94 (0⋅78, 1⋅14) 0⋅519
Supratherapeutic 1⋅33 (1⋅07, 1⋅65) 0⋅009 1⋅19 (0⋅95, 1⋅50) 0⋅132
Values in parentheses are 95 per cent confidence intervals. *The logistic regression model for mortality was adjusted for patient age and sex, beta-blocker
use, chronic kidney disease, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease and admission status (elective,
urgency or emergency). †The model for major adverse events was adjusted for patient age, sex, race, primary payer, beta-blocker use, chronic kidney
disease, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, history of acute myocardial infarction, admission status
(elective, urgent or emergency), teaching and urban hospital status, and physician volume. In a post hoc analysis, using low-intensity statins as a reference
group, moderate, high and supratherapeutic statin intensity did not have a lower odds of death or major adverse events compared with low intensity.
Baseline characteristics of statin users versus
non-users
Some 6497 patients met the inclusion criteria, of whom
3217 (49⋅5 per cent) received statins in hospital (Table 1).
Patients who received statins were slightly younger than
those who did not. There was no difference in sex, race,
insurance status, admission type or hospital location
between statin users and non-users. Similarly, there was no
difference in smoking status, and history of end-stage renal
disease, chronic obstructive pulmonary disease (COPD)
and arrhythmia between the two groups. Statin users were
more likely to have a history of myocardial infarction (MI),
coronary artery disease, congestive heart failure, hyper-
tension and chronic kidney disease. Statin users were also
more likely to have a CCI score of 3 or more, to receive
perioperative beta-blockers in hospital, and be treated in
teaching hospitals.
Baseline characteristics by statin intensity levels
Among statin users, 277 (8⋅6 per cent) received
low-intensity statins, 1987 (61⋅8 per cent) moderate-
intensity statins, 586 (18⋅2 per cent) high-intensity statins,
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 411–418
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and 367 (11⋅4 per cent) received supratherapeutic statins
(Table 1). There was no difference in sex, insurance status,
CCI score, admission type, perioperative beta-blocker use,
smoking status, and history of congestive heart failure,
hypertension, chronic kidney disease, end-stage renal
disease, COPD and arrhythmia between the four statin
intensity groups. Furthermore, hospital characteristics
were comparable between the statin intensity groups.
Patients who received high-intensity statins were more
likely to have a history of MI (22⋅5 versus 11⋅2 per cent)
and coronary artery disease (62⋅5 versus 43⋅3 per cent) than
those on low-intensity statin therapy.
In-hospital postoperative acute myocardial
infarction and major adverse events
MAE occurred in 2847 patients (43⋅8 per cent) undergo-
ing open AAA repair (Table 2). The most common com-
plications were respiratory (21⋅5 per cent), renal (20⋅1 per
cent), cardiac (14⋅3 per cent) and infectious (12⋅5 per cent),
whereas only 159 patients (2⋅4 per cent) developed MI.
There was no difference in the crude risk of develop-
ing the composite MAE, respiratory, renal, haemorrhagic,
infectious and neurological complications between statin
users and non-users. However, the crude risk of postop-
erative MI and the overall rate of cardiac complications
were higher for statin users compared with non-users. On
the contrary, the crude risk of postoperative gastrointesti-
nal complication was lower for statin users than non-users.
Among statin users, the crude risk of developing post-
operative MAE was higher among patients who received
a supratherapeutic dose than in patients taking high-,
moderate- or low-intensity statins (Table 2).
In the adjusted analysis, the odds of developing post-
operative MAE were lower for moderate-intensity statin
users compared with those who did not take statins (odds
ratio (OR) 0⋅86, 95 per cent c.i. 0⋅76 to 0⋅96); however,
there was no difference in the odds of developing MAE for
overall statin use (versus no statins), and for low, high and
supratherapeutic statin intensity versus no statins (Table 3).
In-hospital postoperative mortality and failure
to rescue
The overall crude risk of postoperative death was lower
for statin users than non-users (Table 2). Similarly, the risk
of death among patients who developed MI or MAE was
lower for statin users. There were no differences between
statin intensities in the risk of death from any cause, death
following MI, and death following MAE.
In the adjusted analysis, patients who received a statin
had lower odds of postoperative death compared with
those who did not (OR 0⋅41, 0⋅31 to 0⋅54; P< 0⋅001)
(Table 3). Moreover, moderate-intensity statins had the
lowest adjusted odds of mortality compared with no statin
(OR 0⋅34, 0⋅24 to 0⋅47; P< 0⋅001). Of note, there was no
difference in the adjusted odds of postoperative mortality
between statin intensity levels.
Discussion
In this study, statin use was associated with a 60 per
cent reduction in the odds of death in hospital following
open AAA repair. Although statin users were almost twice
as likely to develop postoperative MI and other cardiac
complications, among patients who developed MI, statin
users had a lower risk of death than non-users (10⋅8 ver-
sus 35⋅0 per cent). In patients who developed MAE, the
risk of death was 55⋅9 per cent lower for statin users than
non-users. This indicates a rescue phenomenon associated
with statin use.
There is inconsistent evidence in the literature describing
the effect of statins on in-hospital outcomes after vascular
surgery. In a study by De Martino and colleagues20, the
risk of in-hospital death was the same for patients receiving
a statin or a statin plus antiplatelet versus no statin among
patients who underwent suprainguinal/infrainguinal
bypass or open AAA repair. Similarly, in an analysis of
4721 Medicare patients, Galiñanes and co-workers12
reported no significant difference in the risk of postopera-
tive in-hospital mortality for statin users versus non-users
after open AAA repair (5⋅1 versus 5⋅4 per cent; P= 0⋅66).
Neither study included an adjusted analysis specifically
among patients who underwent open repair but rather
reported the crude risks of death. In contrast, a study21
of 997 patients undergoing vascular surgery (carotid
endarterectomy, aortic repair and lower extremity revascu-
larization) found statin therapy to be associated with 48 per
cent lower odds of in-hospital complications (death, MI,
congestive heart failure and ventricular tachyarrhythmia)
compared with no statin. The beneficial effects of statins
on long-term outcomes following open aneurysm repair
have been demonstrated in multiple observational studies4.
However, there have been no clinical trials assessing the
association between statin therapy and postoperative out-
comes following open AAA repair specifically. Even after
vascular surgery in general, a recent Cochrane systematic
review15 concluded that evidence is currently lacking with
regard to the short-term effects of statins on postoperative
outcomes.
The present study investigated postoperative outcomes
associated with different intensities of statin therapy specif-
ically following open AAA repair.Moderate-intensity statin
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 411–418
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therapy was associated with the greatest decrease in the
odds of death (66 per cent lower odds of in-hospital death
compared with no statin therapy). Interestingly, there was
no statistical difference in the adjusted odds of in-hospital
mortality between low, moderate, high and suprathera-
peutic statin intensity. Furthermore, moderate-intensity
statin therapy was the only intensity level to be associ-
ated with a lower risk of MAE compared with no statin.
This is an important finding because of the growing
advocacy for the use of intensive statin therapy for the
purpose of lowering morbidity and mortality following
vascular procedures, despite lack of evidence to support
this practice. Most clinical trials comparing outcomes
between different levels of statin intensity were performed
in highly selected non-surgical cohorts, excluding patients
with diabetes, coronary artery disease or chronic kidney
disease22–27. How the findings from these clinical trials
translate into real-world improvement in outcomes is still
a matter of debate. In a retrospective analysis of 15 729
Medicare patients (aged at least 65 years) with coronary
artery disease, O’Brien and colleagues28 found no differ-
ence between high-intensity versus low-moderate-intensity
statin therapy with regard to 1- and 3-year all-cause mor-
tality, major adverse cardiac events (MACE) and all-cause
readmission. Of note, more than 75 per cent of patients
included in the present study were older than 65 years.
Moreover, in an analysis of more than 7000 patients placed
on statin therapy, Ross and co-workers29 noted that the
incidence ofMACEwas not determined by the statin inten-
sity alone, but rather by achieving the target low-density
lipoprotein (LDL) level, and recommended investigating
LDL titration strategies.
The present findings should be interpreted in light of
multiple limitations, one of which concerns the adminis-
tration pattern of statins. It was not possible to quantify
the timing and duration of statin use before admission
to hospital, which would have allowed identification of
patients who used statins on a chronic basis and those
who received statins prophylactically (within 30 days of
admission). It is likely that this study is more representative
of the effect of statins among chronic users, a notion sup-
ported by the observations of Patorno et al.30 in an analysis
of more than half a million patients undergoing elective
non-cardiac procedures. They found that 22⋅5 per cent of
patients received statins in the 6months before non-cardiac
surgery, whereas only 1⋅2 per cent started statin therapy
within 30 days before surgery. Selection bias is inherent in
the retrospective design of this study; it was not possible
to determine why some patients received low-, moderate-
or high-intensity statins. In general, as described in the
current ACC/AHA guidelines19, high-intensity statin
therapy is mainly recommended for patients aged between
40 and 75 years who are at high risk of atheroscle-
rotic cardiovascular diseases, whereas moderate-intensity
statin therapy is recommended for patients older than
75 years. It is unlikely, therefore, that older patients with
worse co-morbidities would be more likely to receive
high-intensity statin therapy than younger patients, so the
risk of selection bias is minimal. More than 10 per cent of
patients who were on statin therapy received a suprather-
apeutic dose (based on the ACC/AHA guidelines19); the
reason for this is unclear. This study is also limited by the
lack of laboratory results, including serum LDL levels. It
has been shown in a meta-analysis31 of patients with coro-
nary artery disease that there is a dose-dependent relation-
ship between reduction in MACE and serum LDL levels.
Adjusting for this variable in logistic regressionmight affect
the relationship between each intensity of statin therapy
and postoperative outcomes. Although the present results
did not find better outcomes associated with higher inten-
sity of statins in this hospital setting, high and suprather-
apeutic intensity of statin therapy might prove beneficial
to long-term outcomes. Finally, although adjustment was
made for the available measured confounders, without con-
ducting an RCT with proper concealed treatment alloca-
tion, unmeasured confounders cannot be balanced between
treatment groups. All findings in this study, therefore,
represent measures of association rather than causation.
This large study has demonstrated that statin use reduces
in-hospital mortality following open AAA repair, with no
evidence to suggest an additive beneficial effect associated
with higher intensities of statin therapy in the hospital set-
ting. This study emphasizes the need for optimum preop-
erative statin therapy before a planned open AAA repair.
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